
Opinion|Videos|December 6, 2023
Other Therapies Approved for Patients With MF
Author(s)Anthony Hunter, MD
Dr Anthony Hunter reviews the other three approved JAK inhibitors for treatment of myelofibrosis: ruxolitinib, fedratinib, and pacritinib.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















